Dendreon Appoints Hans Bishop as Chief Operating Officer
10 Dezembro 2009 - 9:30AM
PR Newswire (US)
- Seasoned Global Oncology Executive Joining Team, Expanding
Company's Commercial Expertise - SEATTLE, Dec. 10
/PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ: DNDN) today
announced that Hans Bishop has joined the Company as chief
operating officer, effective January 4, 2010. Mr. Bishop most
recently served as president of the specialty medicine business at
Bayer, where he was responsible for a diverse portfolio of
oncology, hematology, and neurology products. Mr. Bishop also
served as an executive vice president of Bayer HealthCare LLC. As a
member of the Dendreon executive management team, Mr. Bishop will
be responsible for preparing for and leading the commercial launch
of PROVENGE® (sipuleucel-T), including sales and marketing, as well
as manufacturing, supply chain, quality, and facilities
engineering. "Hans' extensive and successful global commercial
experience will add tremendous value to Dendreon's already strong
executive team as we prepare for the launch of PROVENGE in the
coming year," said Mitchell H. Gold, M.D., president and chief
executive officer. "Hans' deep knowledge of sales and marketing,
manufacturing and operations will be integral to our success as we
transform Dendreon into a commercial organization and work to
fulfill our mission of transforming the lives of patients with
cancer." During his tenure leading specialty medicine at Bayer
HealthCare, Mr. Bishop grew the specialty medicine business into a
euro 3 billion global franchise, including overseeing the
successful growth of Nexavar® and the significant expansion of the
company's oncology pipeline. Prior to this position, Mr. Bishop
served at Chiron Corporation as senior vice president of global
commercial operations, as well as vice president and general
manager of European biopharmaceuticals. In these roles, Mr. Bishop
was responsible for commercial operations for the Global
Biopharmaceuticals Division, leading country operations and
programs such as new product development and pricing. Earlier in
his career, Mr. Bishop served in roles of increasing responsibility
that included sales and marketing as well as business development
at Glaxo Wellcome and SmithKline Beecham. He also spent four years
as the executive vice president of operations with a global telecom
service company, where he managed nine subsidiaries on three
continents, before facilitating the sale of the company in 2004.
Mr. Bishop received a B.S. in chemistry from Brunel University in
London. About Dendreon Dendreon Corporation is a biotechnology
company whose mission is to target cancer and transform lives
through the discovery, development and commercialization of novel
therapeutics. The Company applies its expertise in antigen
identification, engineering and cell processing to produce ACI
product candidates designed to stimulate an immune response.
Dendreon is also developing an orally-available small molecule that
targets TRPM8 that could be applicable to multiple types of cancer
as well as benign prostatic hyperplasia. The Company has its
headquarters in Seattle, Washington, and is traded on the Nasdaq
Global Market under the symbol DNDN. For more information about the
Company and its programs, visit http://www.dendreon.com/.
DATASOURCE: Dendreon Corporation CONTACT: Katherine Stueland, Vice
President, Corporate Communications and Investor Relations of
Dendreon Corporation, +1-206-829-1522, Web Site:
http://www.dendreon.com/
Copyright